Sheridan Snyder, LLB (Hon), OBE – Chief Executive Officer
Sheridan Snyder has over 40 years experience in creating successful, sustainable companies. He was an original founder of Genzyme Inc. and, most recently, the CEO of Upstate Inc. Mr. Snyder is chairman of BioCatalyst International, the investment and startup management company that is currently the sole investor in MolecularMD. Former companies – with a combined market value of over $18 billion – include Genzyme, the Instapak division of Sealed Air Corp. and Dyax.

Dan Snyder, MBA – President, COO
Dan Snyder has more than 15 years of experience in the life science research and diagnostic fields supporting the market development of high value products and services to both pharmaceutical and academia clients. Mr. Snyder has worked extensively in supporting new product introductions and rapid market adoption for novel proteomic and genomic technologies. His commitment to customer satisfaction and close interaction with MolecularMD’s assay development laboratory helps to ensure MolecularMD meets or surpasses all client expectations.

Stephane Wong, Ph.D., MBA – Chief Scientific Officer
Stephane Wong has over 10 years’ experience in cancer research and molecular testing, including numerous publications in the field of chronic myelogenous leukemia. Dr. Wong is one of the founders of MolecularMD and led the team as the Chief Operating Officer to develop and commercialize BCR-ABL tests as well as assays in the solid tumor space adhering to regulations including CLIA/CAP. Currently, Dr. Wong is the Chief Scientific Officer focusing on novel platform development for the laboratory and companion diagnostics with pharmaceutical partners.

Nasry Yassa – Vice President of Operations
Nasry Yassa has over 27 years of clinical diagnostics experience. He is responsible for running day to day operations related to clinical laboratory services and research and development. Prior to MolecularMD, Mr. Yassa was the President and COO of PIL Diagnostics Inc. and was responsible for expanding the clinical trials operation for Phase I-IV studies. Before that, Mr. Yassa served as Vice President, Office of Technology Management at Pathway Diagnostics where he managed a multi-disciplinary organization working to identify and in-license novel technology from discovery companies, academia and bio-pharma in all disease areas.

Chad Galderisi, D.O., Laboratory Director
Chad Galderisi is one of the scientific founders of MolecularMD with over 10 years of experience in molecular testing and diagnostic surgical pathology. Dr. Galderisi is board certified in Molecular Genetic Pathology and an Adjunct Assistant Professor at Oregon Health and Science University. He currently serves as Laboratory Director and member of the Board of Directors for MolecularMD, Corp.